SAN DIEGO--(BUSINESS WIRE)--May 31, 2018--
Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated
to the development of best-in-class therapeutics that improve and extend
the lives of patients with cancer, today announced that it will present
at the Jefferies 2018 Global Healthcare Conference on Wednesday,
June 6, 2018, at 2:30 p.m. Eastern Time.
About Odonate Therapeutics, Inc.
Odonate Therapeutics, Inc. is a pharmaceutical company dedicated to the
development of best-in-class therapeutics that improve and extend the
lives of patients with cancer. Odonate’s initial focus is on the
development of tesetaxel, an investigational, orally administered
chemotherapy agent belonging to a class of drugs known as taxanes, which
are widely used in the treatment of cancer. Odonate recently initiated
CONTESSA, a multinational, multicenter, randomized, Phase 3 study of
tesetaxel in patients with locally advanced or metastatic breast cancer.
Odonate’s goal for tesetaxel is to develop an effective chemotherapy
choice for patients that provides quality-of-life advantages over
current alternatives. To learn more, please visit www.odonate.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180531005468/en/
Source: Odonate Therapeutics, Inc.
Odonate Therapeutics, Inc.
John G. Lemkey